Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Switch Clear all
Active, not recruiting Phase 3 Interventional

Entecavir to TAF Switch

NCT03489239
View directory record Official record
Conditions
Hepatitis B
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Original Study

NCT00567281
View directory record Official record
Conditions
Schizophrenia
Interventions
Magstim Rapid-2 system triggering Magstim Super Rapid system
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 18, 2026, 10:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

NCT03288493
View directory record Official record
Conditions
Multiple Myeloma
Interventions
P-BCMA-101 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Gilbert, Arizona • Davis, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 18, 2026, 10:02 AM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Telemedicine in Primary Care

NCT04684836
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure, Diabetes, Hypertension
Interventions
Exposure to telemedicine, after the onset of the pandemic
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years and older
Enrollment
33,100 participants
Timeline
2021 – 2022
U.S. locations
4
States / cities
Gainesville, New York • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

NCT02729714
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Burdick, Daniel, M.D.
Individual
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 18, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

NCT07006506
View directory record Official record
Conditions
Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy
Interventions
Belumosudil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients

NCT01093703
View directory record Official record
Conditions
Blood Pressure Control, Kidney Transplant Recipient
Interventions
Medication Adjustment
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 18, 2026, 10:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

NCT03911973
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
Gedatolisib, Talazoparib
Drug
Lead sponsor
Kari Wisinski
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 18, 2026, 10:02 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

NCT05816382
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
TAK-861
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Redwood City, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)

NCT01347073
View directory record Official record
Conditions
Urea Cycle Disorders
Interventions
HPN-100
Drug
Lead sponsor
Amgen
Industry
Eligibility
29 Days to 6 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Portland, Maine + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 18, 2026, 10:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

DS vs SIPS-Bariatric Surgery Comparasion

NCT03236142
View directory record Official record
Conditions
Bariatric Surgery Candidate
Interventions
SIPS Operation, Standard Duodenal Switch Operation
Procedure
Lead sponsor
Reading Health System
Other
Eligibility
20 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 18, 2026, 10:02 AM EDT
Not listed Not applicable Interventional

Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D

NCT04614623
View directory record Official record
Conditions
Type1diabetes
Interventions
AHCL pump, Video conferencing Application
Device · Other
Lead sponsor
Children's Hospital New Orleans, LA
Other
Eligibility
10 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 18, 2026, 10:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Experiment 3: Mixed vs Blocked; Dashboard Paradigm

NCT06934213
View directory record Official record
Conditions
Vision, Healthy, Attention
Interventions
Choice, Mixed trials
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 10:02 AM EDT
Recruiting Not applicable Interventional

Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy

NCT06948058
View directory record Official record
Conditions
Smoking Cessation, Obesity and Obesity-related Medical Conditions
Interventions
Electronic Cigarettes (EC), Nicotine replacement therapy (NRT)
Other
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

NCT04070326
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Lanadelumab
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 11 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Santa Monica, California • Walnut Creek, California • Centennial, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Group Drum-Based Music Therapy Intervention for Parkinson's Disease/Huntington's Disease

NCT05157074
View directory record Official record
Conditions
Parkinson Disease, Huntington Disease
Interventions
Group Drumming Music Therapy
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 18, 2026, 10:02 AM EDT
Terminated Phase 4 Interventional Results available

Artery Elasticity After Switch From Epzicom to Truvada

NCT00998582
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 18, 2026, 10:02 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Crovalimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 18, 2026, 10:02 AM EDT
Completed No phase listed Observational

Genetic Determinants of Congenital Heart Disease Outcomes

NCT01656941
View directory record Official record
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Hypoplastic Right Heart Syndrome, d-Transposition of the Great Arteries
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Up to 30 Days
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 18, 2026, 10:02 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

NCT06411223
View directory record Official record
Conditions
Hiv
Interventions
Collaborative drug therapy management model, Cabotegravir/Rilpivirine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Not applicable Interventional Results available

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

NCT00749580
View directory record Official record
Conditions
Virus Diseases, HIV
Interventions
Switch NRTIs as a Backbone to Raltegravir
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SWITCH Implementation Effectiveness Trial

NCT04045288
View directory record Official record
Conditions
Sedentary Behavior, Health Promotion, Overweight and Obesity, Healthy Lifestyle, Diet, Healthy
Interventions
Standard Implementation, Enhanced Implementation
Behavioral
Lead sponsor
Iowa State University
Other
Eligibility
9 Years to 11 Years
Enrollment
1,984 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 18, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

NCT01968213
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Rucaparib, Placebo
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 18, 2026, 10:02 AM EDT